Search Results - "Alloway, R.R"

Prospective Iterative Trial of Proteasome Inhibitor‐Based Desensitization by Woodle, E. S., Shields, A. R., Ejaz, N. S., Sadaka, B., Girnita, A., Walsh, R. C., Alloway, R. R., Brailey, P., Cardi, M. A., Abu Jawdeh, B. G., Roy‐Chaudhury, P., Govil, A., Mogilishetty, G.

“…A prospective iterative trial of proteasome inhibitor (PI)‐based therapy for reducing HLA antibody (Ab) levels was conducted in five phases differing in…”
Get full text

Evolution of the Role of the Transplant Pharmacist on the Multidisciplinary Transplant Team by Alloway, R. R., Dupuis, R., Gabardi, S., Kaiser, T. E., Taber, D. J., Tichy, E. M., Weimert‐Pilch, N. A.

“…Transplant pharmacists have been recognized as an essential part of the transplant team by their colleagues along with several governing and professional…”
Get full text

Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report by Dedhia, P, Govil, A, Mogilishetty, G, Alloway, R.R, Woodle, E.S, Abu Jawdeh, B.G

“…Abstract Background Atypical hemolytic uremic syndrome (aHUS) is associated with significant morbidity and mortality and occurs due to genetic or acquired…”
Get full text

Randomized Controlled Pilot Study of B Cell–Targeted Induction Therapy in HLA Sensitized Kidney Transplant Recipients by Ejaz, N. S., Shields, A. R., Alloway, R. R., Sadaka, B., Girnita, A. L., Mogilishetty, G., Cardi, M., Woodle, E. S.

“…Optimal induction regimens for patients at high risk for antibody and/or cell–mediated rejection have not been established. This pilot, prospective, randomized…”
Get full text

Complete Remission of Post-transplantation Recurrence of Focal Segmental Glomerulosclerosis With the Use of Adrenocorticotrophic Hormone Gel: Case Report by Mittal, T, Dedhia, P, Roy-Chaudhury, P, Abu Jawdeh, B.G, Mogilishetty, G, Cuffy, M.C, Alloway, R.R, Woodle, E.S, Govil, A

“…Abstract Background Post-transplantation recurrence of primary focal and segmental glomerulosclerosis (FSGS) is estimated to occur in 30%–50% of cases and…”
Get full text

Case Report: Hemolytic Anemia Following Deceased Donor Renal Transplantation Associated With Tranexamic Acid Administration for Disseminated Intravascular Coagulation by Revollo, J.Y, Cuffy, M.C, Witte, D.P, Paterno, F, Alloway, R.R, Woodle, E.S

“…Abstract Background Long-term outcomes of kidney transplantation with organs from donors with disseminated intravascular coagulation (DIC) are comparable with…”
Get full text

Case Report: Successful Living Donor Kidney Transplantation in a Highly Human Leukocyte Antigen-Sensitized Recipient With a Positive Cytotoxic Crossmatch Using Bortezomib-Based Desensitization Without Intravenous Immunoglobulin by Revollo, J.Y, Cuffy, M.C, Abu Jawdeh, B.G, Paterno, F, Girnita, A, Brailey, P, Alloway, R.R, Woodle, E.S

“…Abstract Background Highly sensitized patients, who produce antibodies against multiple anti-human leukocyte antigens, have significantly reduced chances for…”
Get full text

Proteasome Inhibition Reduces Donor-Specific Antibody Levels by Everly, M.J, Everly, J.J, Susskind, B, Brailey, P, Arend, L.J, Alloway, R.R, Roy-Chaudhury, P, Govil, A, Mogilishetty, G, Rike, A.H, Cardi, M, Wadih, G, Brown, E, Tevar, A, Woodle, E.S

“…Abstract Background Current antibody-mediated rejection (AMR) therapies (intravenous immunoglobulin, apheresis, rituximab, polyclonal antibodies) do not target…”
Get full text

45-OR: Renal transplant patients with late antibody mediated rejection exhibit more IgG3 and/or multiple IgG subtype combinations when compared to early antibody mediated rejection by Girnita, A.L, Brailey, P, Portwood, E, Alloway, R.R, Rike-Shields, A, Sadaka, B, Woodle, E.S

Get full text

30-P Differential antigen- and epitope-based reduction of HLA-specific antibody in renal transplant candidates under proteasome inhibitor-based desensitization by Girnita, A.L, Brailey, P, Sadaka, B, Rike-Shields, A, Cardi, M, Mogilishetty, G, Alloway, R.R, Woodle, E.S

Get full text

75-P: Preformed Low Reactive Anti-HLA Antibodies Are Associated With Majority of Early Antibody-Mediated Rejection in Renal Transplantation by Brailey, P, Woodle, E.S, Alloway, R.R, Tevar, A.D, Cardi, M, Portwood, E, Mogilishetty, G, Govil, A, Rike, A.H, Walsh, R.C, Wall, G, Girnita, A.L

Get full text

A Steady‐State Head‐to‐Head Pharmacokinetic Comparison of All FK‐506 (Tacrolimus) Formulations (ASTCOFF): An Open‐Label, Prospective, Randomized, Two‐Arm, Three‐Period Crossover Study by Tremblay, S., Nigro, V., Weinberg, J., Woodle, E. S., Alloway, R. R.

“…This two‐sequence, three‐period crossover study is the first pharmacokinetic (PK) study to compare all three innovator formulations of tacrolimus (twice‐daily…”
Get full text

Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward by Stegall, M. D., Morris, R. E., Alloway, R. R., Mannon, R. B.

“…The development of new immunosuppressive drugs has slowed markedly over the past several years, and the outlook that improved therapy will be available to the…”
Get full text

Laparoscopic sleeve gastrectomy improves renal transplant candidacy and posttransplant outcomes in morbidly obese patients by Kim, Y., Jung, A. D., Dhar, V. K., Tadros, J. S., Schauer, D. P., Smith, E. P., Hanseman, D. J., Cuffy, M. C., Alloway, R. R., Shields, A. R., Shah, S. A., Woodle, E. S., Diwan, T. S.

“…Morbid obesity is a barrier to kidney transplantation due to inferior outcomes, including higher rates of new‐onset diabetes after transplantation (NODAT),…”
Get full text

Proteasomal adaptations underlying carfilzomib‐resistance in human bone marrow plasma cells by Woodle, E. Steve, Tremblay, Simon, Brailey, Paul, Girnita, Alin, Alloway, Rita R., Aronow, Bruce, Dasgupta, Nupur, Ebstein, Frederic, Kloetzel, Peter‐Michael, Lee, Min Jae, Kim, Kyung B., Singh, Harinder, Driscoll, James J.

“…Donor‐specific antibodies (DSAs) have a deleterious effect on allografts and remain a major immunologic barrier in transplantation. Current therapies to…”
Get full text

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients by Alloway, R. R., Sadaka, B., Trofe‐Clark, J., Wiland, A., Bloom, R. D.

“…Pharmacokinetic analyses comparing generic tacrolimus preparations versus the reference drug in kidney transplant patients are lacking. A prospective,…”
Get full text

Reply to “Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View” by Tremblay, S., Nigro, V., Woodle, E. S., Alloway, R. R.

Get full text

Immunosuppression, Generic Drugs and the FDA by Trofe‐Clark, J., Gabardi, S., McDevitt‐Potter, L., Alloway, R. R.

Get full text

Addressing morbid obesity as a barrier to renal transplantation with laparoscopic sleeve gastrectomy by Freeman, C M, Woodle, E S, Shi, J, Alexander, J W, Leggett, P L, Shah, S A, Paterno, F, Cuffy, M C, Govil, A, Mogilishetty, G, Alloway, R R, Hanseman, D, Cardi, M, Diwan, T S

“…Morbid obesity is a barrier to renal transplantation and is inadequately addressed by medical therapy. We present results of a prospective evaluation of…”
Get full text

Immunosuppression and merkel cell cancer by Buell, J.F, Trofe, J, Hanaway, M.J, Beebe, T.M, Gross, T.G, Alloway, R.R, First, M.R, Woodle, E.S

Get full text